You are here

  • Home
  • Archive
  • Volume 9, Issue 6
  • Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma

Article metrics

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Tumor-derived lactate inhibit the efficacy of lenvatinib through regulating PD-L1 expression on neutrophil in hepatocellular carcinoma

 

Online download statistics by month:

Online download statistics by month: June 2021 to July 2025

AbstractFullPdf
Jun 2021206206115
Jul 2021534534317
Aug 2021330330109
Sep 202121121173
Oct 2021247247103
Nov 202118518487
Dec 202120120168
Jan 202221621966
Feb 202250250376
Mar 2022382385103
Apr 202224225198
May 2022182187105
Jun 2022151161103
Jul 2022144147112
Aug 202212913266
Sep 202215215984
Oct 202213813979
Nov 202214714774
Dec 202213313351
Jan 202321922066
Feb 202336836891
Mar 202323623888
Apr 202326526574
May 202381481573
Jun 202378278269
Jul 202367767759
Aug 202375675750
Sep 202370670765
Oct 202338338672
Nov 202340140184
Dec 2023349349109
Jan 2024467469120
Feb 202441041185
Mar 2024522523146
Apr 2024546547124
May 2024428431108
Jun 202440340690
Jul 202436236387
Aug 202425325364
Sep 2024264264142
Oct 2024302302118
Nov 202428028183
Dec 2024352358135
Jan 2025322322106
Feb 2025289289138
Mar 2025388388122
Apr 2025350353149
May 2025222225161
Jun 2025979840
Jul 2025110
Total16646167254807